**Annex I to the CLH report**

Proposal for Harmonised Classification and Labelling

**Based on Regulation (EC) No 1272/2008 (CLP Regulation),**

**Annex VI, Part 2**

International Chemical Identification:

**EC Number:**

**CAS Number:**

**Index Number:**

**Contact details for dossier submitter:**

**Version number: Date:**

***Note on confidential information***

**Please be aware that this report is intended to be made publicly available. Therefore it should not contain any confidential information. Such information should be provided in a separate confidential Annex to this report, clearly marked as such.**

**CONTENTS**

[1 PHYSICAL HAZARDS 8](#_Toc141352862)

[1.1 Explosives 8](#_Toc141352863)

[1.1.1 [Study 1] 8](#_Toc141352864)

[1.1.2 [Study 2] etc. 8](#_Toc141352865)

[1.2 Flammable gases (including chemically unstable gases) 8](#_Toc141352866)

[1.2.1 [Study 1] 8](#_Toc141352867)

[1.2.2 [Study 2] etc. 9](#_Toc141352868)

[1.3 Oxidising gases 9](#_Toc141352869)

[1.3.1 [Study 1] 9](#_Toc141352870)

[1.3.2 [Study 2] etc. 9](#_Toc141352871)

[1.4 Gases under pressure 10](#_Toc141352872)

[1.4.1 [Study 1] 10](#_Toc141352873)

[1.4.2 [Study 2] etc. 10](#_Toc141352874)

[1.5 Flammable liquids 10](#_Toc141352875)

[1.5.1 [Study 1] 10](#_Toc141352876)

[1.5.2 [Study 2] etc. 11](#_Toc141352877)

[1.6 Flammable solids 11](#_Toc141352878)

[1.6.1 [Study 1] 11](#_Toc141352879)

[1.6.2 [Study 2] etc. 11](#_Toc141352880)

[1.7 Self-reactive substances 12](#_Toc141352881)

[1.7.1 [Study 1] 12](#_Toc141352882)

[1.7.2 [Study 2] etc. 12](#_Toc141352883)

[1.8 Pyrophoric liquids 12](#_Toc141352884)

[1.8.1 [Study 1] 12](#_Toc141352885)

[1.8.2 [Study 2] etc. 13](#_Toc141352886)

[1.9 Pyrophoric solids 13](#_Toc141352887)

[1.9.1 [Study 1] 13](#_Toc141352888)

[1.9.2 [Study 2] etc. 13](#_Toc141352889)

[1.10 Self-heating substances 13](#_Toc141352890)

[1.10.1 [Study 1] 13](#_Toc141352891)

[1.10.2 [Study 2] etc. 14](#_Toc141352892)

[1.11 Substances which in contact with water emit flammable gases 14](#_Toc141352893)

[1.11.1 [Study 1] 14](#_Toc141352894)

[1.11.2 [Study 2] etc. 14](#_Toc141352895)

[1.12 Oxidising liquids 14](#_Toc141352896)

[1.12.1 [Study 1] 15](#_Toc141352897)

[1.12.2 [Study 2] etc. 15](#_Toc141352898)

[1.13 Oxidising solids 15](#_Toc141352899)

[1.13.1 [Study 1] 15](#_Toc141352900)

[1.13.2 [Study 2] etc. 16](#_Toc141352901)

[1.14 Organic peroxides 16](#_Toc141352902)

[1.14.1 [Study 1] 16](#_Toc141352903)

[1.14.2 [Study 2] etc. 16](#_Toc141352904)

[1.15 Corrosive to metals 16](#_Toc141352905)

[1.15.1 [Study 1] 16](#_Toc141352906)

[1.15.2 [Study 2] etc. 17](#_Toc141352907)

[2 TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION) 17](#_Toc141352908)

[2.1.1 [Study 1] 17](#_Toc141352909)

[2.1.2 [Study 2] etc. 18](#_Toc141352910)

[3 HEALTH HAZARDS 18](#_Toc141352911)

[3.1 Acute toxicity - oral route 18](#_Toc141352912)

[3.1.1 Animal data 18](#_Toc141352913)

[3.1.1.1 [Study 1] 18](#_Toc141352914)

[3.1.1.2 [Study 2] etc. 19](#_Toc141352915)

[3.1.2 Human data 19](#_Toc141352916)

[3.1.2.1 [Study 1] 19](#_Toc141352917)

[3.1.2.2 [Study 2] etc. 20](#_Toc141352918)

[3.1.3 Other data 20](#_Toc141352919)

[3.1.3.1 [Study 1] 20](#_Toc141352920)

[3.1.3.2 [Study 2] etc. 20](#_Toc141352921)

[3.2 Acute toxicity - dermal route 20](#_Toc141352922)

[3.2.1 Animal data 20](#_Toc141352923)

[3.2.1.1 [Study 1] 20](#_Toc141352924)

[3.2.1.2 [Study 2] etc. 22](#_Toc141352925)

[3.2.2 Human data 22](#_Toc141352926)

[3.2.2.1 [Study 1] 22](#_Toc141352927)

[3.2.2.2 [Study 2] etc. 22](#_Toc141352928)

[3.2.3 Other data 22](#_Toc141352929)

[3.2.3.1 [Study 1] 22](#_Toc141352930)

[3.2.3.2 [Study 2] etc. 23](#_Toc141352931)

[3.3 Acute toxicity - inhalation route 23](#_Toc141352932)

[3.3.1 Animal data 23](#_Toc141352933)

[3.3.1.1 [Study 1] 23](#_Toc141352934)

[3.3.1.2 [Study 2] etc. 24](#_Toc141352935)

[3.3.2 Human data 24](#_Toc141352936)

[3.3.2.1 [Study 1] 24](#_Toc141352937)

[3.3.2.2 [Study 2] etc. 24](#_Toc141352938)

[3.3.3 Other data 24](#_Toc141352939)

[3.3.3.1 [Study 1] 24](#_Toc141352940)

[3.3.3.2 [Study 2] etc. 25](#_Toc141352941)

[3.4 Skin corrosion/irritation 25](#_Toc141352942)

[3.4.1 Animal data 25](#_Toc141352943)

[3.4.1.1 [Study 1] 25](#_Toc141352944)

[3.4.1.2 [Study 2] etc. 26](#_Toc141352945)

[3.4.2 Human data 26](#_Toc141352946)

[3.4.2.1 [Study 1] 26](#_Toc141352947)

[3.4.2.2 [Study 2] etc. 27](#_Toc141352948)

[3.4.3 Other data 27](#_Toc141352949)

[3.4.3.1 [Study 1] 27](#_Toc141352950)

[3.4.3.2 [Study 2] etc. 27](#_Toc141352951)

[3.5 Serious eye damage/eye irritation 27](#_Toc141352952)

[3.5.1 Animal data 27](#_Toc141352953)

[3.5.1.1 [Study 1] 27](#_Toc141352954)

[3.5.1.2 [Study 2] etc. 28](#_Toc141352955)

[3.5.2 Human data 29](#_Toc141352956)

[3.5.2.1 [Study 1] 29](#_Toc141352957)

[3.5.2.2 [Study 2] etc. 29](#_Toc141352958)

[3.5.3 Other data 29](#_Toc141352959)

[3.5.3.1 [Study 1] 29](#_Toc141352960)

[3.5.3.2 [Study 2] etc. 29](#_Toc141352961)

[3.6 Respiratory sensitisation 29](#_Toc141352962)

[3.6.1 Animal data 29](#_Toc141352963)

[3.6.1.1 [Study 1] 30](#_Toc141352964)

[3.6.1.2 [Study 2] etc. 31](#_Toc141352965)

[3.6.2 Human data 31](#_Toc141352966)

[3.6.2.1 [Study 1] 31](#_Toc141352967)

[3.6.2.2 [Study 2] etc. 31](#_Toc141352968)

[3.6.3 Other data 31](#_Toc141352969)

[3.6.3.1 [Study 1] 31](#_Toc141352970)

[3.6.3.2 [Study 2] etc. 31](#_Toc141352971)

[3.7 Skin sensitisation 31](#_Toc141352972)

[3.7.1 Animal data 31](#_Toc141352973)

[3.7.1.1 [Study 1] 32](#_Toc141352974)

[3.7.1.2 [Study 2] etc. 33](#_Toc141352975)

[3.7.2 Human data 33](#_Toc141352976)

[3.7.2.1 [Study 1] 33](#_Toc141352977)

[3.7.2.2 [Study 2] etc. 34](#_Toc141352978)

[3.7.3 Other data 34](#_Toc141352979)

[3.7.3.1 [Study 1] 34](#_Toc141352980)

[3.7.3.2 [Study 2] etc. 34](#_Toc141352981)

[3.8 Germ cell mutagenicity 34](#_Toc141352982)

[3.8.1 In vitro data 34](#_Toc141352983)

[3.8.1.1 [Study 1] 34](#_Toc141352984)

[3.8.1.2 [Study 2] etc. 36](#_Toc141352985)

[3.8.2 Animal data 36](#_Toc141352986)

[3.8.2.1 [Study 1] 36](#_Toc141352987)

[3.8.2.2 [Study 2] etc. 37](#_Toc141352988)

[3.8.3 Human data 37](#_Toc141352989)

[3.8.3.1 [Study 1] 37](#_Toc141352990)

[3.8.3.2 [Study 2] etc. 38](#_Toc141352991)

[3.8.4 Other data 38](#_Toc141352992)

[3.8.4.1 [Study 1] 38](#_Toc141352993)

[3.8.4.2 [Study 2] etc. 38](#_Toc141352994)

[3.9 Carcinogenicity 38](#_Toc141352995)

[3.9.1 Animal data 38](#_Toc141352996)

[3.9.1.1 [Study 1] 38](#_Toc141352997)

[3.9.1.2 [Study 2] etc. 40](#_Toc141352998)

[3.9.2 Human data 40](#_Toc141352999)

[3.9.2.1 [Study 1] 40](#_Toc141353000)

[3.9.2.2 [Study 2] etc. 41](#_Toc141353001)

[3.9.3 In vitro data (e.g. in vitro germ cell and somatic cell mutagenicity studies, cell transformation assays, gap junction intercellular communication tests) 41](#_Toc141353002)

[3.9.3.1 [Study 1] 41](#_Toc141353003)

[3.9.3.1 [Study 2] etc. 41](#_Toc141353004)

[3.9.4 Other data (e.g. studies on mechanism of action) 41](#_Toc141353005)

[3.9.4.1 [Study 1] 41](#_Toc141353006)

[3.9.4.2 [Study 2] etc. 41](#_Toc141353007)

[3.10 Reproductive toxicity 42](#_Toc141353008)

[3.10.1 Animal data 42](#_Toc141353009)

[3.10.1.1 [Study 1] 42](#_Toc141353010)

[3.10.1.2 [Study 2] etc. 44](#_Toc141353011)

[3.10.2 Human data 44](#_Toc141353012)

[3.10.2.1 [Study 1] 44](#_Toc141353013)

[3.10.2.2 [Study 2] etc. 45](#_Toc141353014)

[3.10.3 Other data (e.g. studies on mechanism of action) 45](#_Toc141353015)

[3.10.3.1 [Study 1] 45](#_Toc141353016)

[3.10.3.2 [Study 2] etc. 45](#_Toc141353017)

[3.11 Specific target organ toxicity – single exposure 45](#_Toc141353018)

[3.11.1 Animal data 45](#_Toc141353019)

[3.11.1.1 [Study 1] 45](#_Toc141353020)

[3.11.1.2 [Study 2] etc. 47](#_Toc141353021)

[3.11.2 Human data 47](#_Toc141353022)

[3.11.2.1 [Study 1] 47](#_Toc141353023)

[3.11.2.2 [Study 2] etc. 47](#_Toc141353024)

[3.11.3 Other data 48](#_Toc141353025)

[3.11.3.1 [Study 1] 48](#_Toc141353026)

[3.11.3.2 [Study 2] etc. 48](#_Toc141353027)

[3.12 Specific target organ toxicity – repeated exposure 48](#_Toc141353028)

[3.12.1 Animal data 48](#_Toc141353029)

[3.12.1.1 [Study 1] 48](#_Toc141353030)

[3.12.1.2 [Study 2] etc. 50](#_Toc141353031)

[3.12.2 Human data 50](#_Toc141353032)

[3.12.2.1 [Study 1] 50](#_Toc141353033)

[3.12.2.2 [Study 2] etc. 50](#_Toc141353034)

[3.12.3 Other data 50](#_Toc141353035)

[3.12.3.1 [Study 1] 50](#_Toc141353036)

[3.12.3.2 [Study 2] etc. 51](#_Toc141353037)

[3.13 Aspiration hazard 51](#_Toc141353038)

[3.13.1 Animal data 51](#_Toc141353039)

[3.13.1.1 [Study 1] 51](#_Toc141353040)

[3.13.1.2 [Study 2] etc. 51](#_Toc141353041)

[3.13.2 Human data 52](#_Toc141353042)

[3.13.2.1 [Study 1] 52](#_Toc141353043)

[3.13.2.2 [Study 2] etc. 52](#_Toc141353044)

[3.13.3 Other data 52](#_Toc141353045)

[3.13.3.1 [Study 1] 52](#_Toc141353046)

[3.13.3.2 [Study 2] etc. 52](#_Toc141353047)

[3.14 ENDOCRINE DISRUPTION FOR HUMAN HEALTH 53](#_Toc141353048)

[3.14.1 Animal data 53](#_Toc141353049)

[3.14.2 Human data 53](#_Toc141353050)

[3.14.3 Other data (e.g. in vitro data, in silico data, mechanistic data) 53](#_Toc141353051)

[4 ENVIRONMENTAL HAZARDS 53](#_Toc141353052)

[4.1 Degradation 53](#_Toc141353053)

[4.1.1 Ready biodegradability (screening studies) 53](#_Toc141353055)

[4.1.2 BOD5/COD 55](#_Toc141353056)

[4.1.3 Aquatic simulation tests 55](#_Toc141353057)

[4.1.4 Other degradability studies 57](#_Toc141353058)

[4.2 Bioaccumulation 57](#_Toc141353059)

[4.2.1 Bioaccumulation test on fish 57](#_Toc141353060)

[4.2.2 Bioaccumulation test with other organisms 59](#_Toc141353061)

[4.3 Acute toxicity 60](#_Toc141353062)

[4.3.1 Short-term toxicity to fish 60](#_Toc141353063)

[4.3.2 Short-term toxicity to aquatic invertebrates 62](#_Toc141353064)

[4.3.3 Algal growth inhibition tests 63](#_Toc141353065)

[4.3.4 Lemna sp. growth inhibition test 64](#_Toc141353066)

[4.4 Chronic toxicity 65](#_Toc141353067)

[4.4.1 Fish early-life stage (FELS) toxicity test 65](#_Toc141353068)

[4.4.2 Fish short-term toxicity test on embryo and sac-fry stages 67](#_Toc141353069)

[4.4.3 Aquatic Toxicity – Fish, juvenile growth test 68](#_Toc141353070)

[4.4.4 Chronic toxicity to aquatic invertebrates 69](#_Toc141353071)

[4.4.5 Chronic toxicity to algae or aquatic plants 70](#_Toc141353072)

[4.5 Acute and/or chronic toxicity to other aquatic organisms 70](#_Toc141353073)

[OECD TG 218: Sediment-Water Chironomid Toxicity Using Spiked Sediment and 70](#_Toc141353074)

[OECD TG 219: Sediment-Water Chironomid Toxicity Using Spiked Water 70](#_Toc141353075)

[OECD TG 225: Sediment-Water Lumbriculus Toxicity Test Using Spiked Sediment 71](#_Toc141353076)

[4.6 ENDOCRINE DISRUPTION FOR THE ENVIRONMENT 71](#_Toc141353077)

[4.6.1 Animal data 71](#_Toc141353078)

[4.6.2 Other data (e.g. in vitro data, in silico data, mechanistic data) 72](#_Toc141353079)

[5 PERSISTENT, BIOACCUMULATIVE AND TOXIC (PBT) OR VERY PERSISTENT, VERY BIOACCUMULATIVE (VPVB) PROPERTIES UNDER CLP ANNEX I, 4.3 72](#_Toc141353080)

[5.1 [Add your text here] 72](#_Toc141353081)

[5.1.1 [Add your text here] 72](#_Toc141353082)

[5.1.2 [Add your text here] 72](#_Toc141353083)

[5.2 [Add your text here] 72](#_Toc141353084)

[5.2.1 [Add your text here] 72](#_Toc141353085)

[5.2.2 [Add your text here] 73](#_Toc141353086)

[5.3 [Add your text here] 73](#_Toc141353087)

[5.3.1 [Add your text here] 73](#_Toc141353088)

[5.3.2 [Add your text here] 73](#_Toc141353089)

[6 PERSISTENT, MOBILE AND TOXIC (PMT) OR VERY PERSISTENT, VERY MOBILE (vPvM) PROPERTIES UNDER CLP ANNEX I, 4.4 73](#_Toc141353090)

[6.1 [Add your text here] 73](#_Toc141353091)

[6.1.1 [Add your text here] 74](#_Toc141353092)

[6.1.2 [Add your text here] 74](#_Toc141353093)

[6.2 [Add your text here] 74](#_Toc141353094)

[6.2.1 [Add your text here] 74](#_Toc141353095)

[6.2.2 [Add your text here] 74](#_Toc141353096)

[6.3 [Add your text here] 74](#_Toc141353097)

[6.3.1 [Add your text here] 74](#_Toc141353098)

[6.3.2 [Add your text here] 75](#_Toc141353099)

[7 ADDITIONAL HAZARDS: HAZARDOUS TO THE OZONE LAYER 75](#_Toc141353100)

**SUPPORT ON HOW TO COMPILE ANNEX I TO THE CLH REPORT**

*Annex I to the CLH report may be compiled from DARs, CARs and/or other sources. Non-confidential DAR/CAR can be annexed as such provided that it has sufficient level of details on the studies. The DS is encouraged to remove any irrelevant parts of the DAR/CAR. The DS must ensure that Annex I can be published during public consultation, i.e. it does not contain any confidential information.*

*For support, below is an example on how each study could be presented individually under its own subchapter including the study reference, detailed study summary and results. The format of the detailed study summary of an individual study is flexible as long as the summary is clearly reported and under a correct hazard class. Detailed support can be found below under each subchapter. For the hazard classes introduced in 2023 (ED HH, ED ENV, PBT, vPvB, PMT, vPvM) the dossier submitter can use its discretion how to organise the data in Annex I. The main (sub)headings are provided for those hazard classes in this template. The dossier submitter needs to provide in the CLH report sufficient amount and detail of data for concluding on the hazard class, and the Annex I can be used to present e.g. non-standard methods in detail, tabular data, details of the historical control data etc.*

*If DAR/CAR is annexed to the CLH report as Annex I, it must be indicated clearly in the evaluation part of the report where in Annex I the relevant study can be found. If read-across to structurally or mechanistically similar substance is used please provide a justification for using data from this substance and, if known, present the calculations to convert dose/concentration levels from the test substance to the substance for which CLH is proposed. Please provide also a justification for providing non-testing data by any other approaches such as quantitative structure-activity relationships (QSARs) or grouping methods. Support on* *grouping of substances and read-across can be found in the following links:*

[https://echa.europa.eu/documents/10162/17224/information\_requirements\_r6\_en.pdf](https://echa.europa.eu/documents/10162/17224/information_requirements_r6_en.pdf" \o "https://echa.europa.eu/documents/10162/17224/information_requirements_r6_en.pdf" \t "_blank)

[https://echa.europa.eu/documents/10162/2324906/appendix\_r6\_nanomaterials\_en.pdf](https://echa.europa.eu/documents/10162/2324906/appendix_r6_nanomaterials_en.pdf/71ad76f0-ab4c-fb04-acba-074cf045eaaa?t=1575287755659)

<http://www.qsartoolbox.org/>

<http://www.oecd.org/chemicalsafety/risk-assessment/groupingofchemicalschemicalcategoriesandread-across.htm>

<http://echa.europa.eu/en/view-article/-/journal_content/title/assessing-read-across-how-echa-does-it>

# PHYSICAL HAZARDS

*Ideally the reported study should comply with the indication provided in ECHA guidance “How to report robust study summaries”.*

## Explosives

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *pre-treatment of the sample (crushed, sieved, etc.)*
* *reference substance*
* *if alternative apparatus is used, justification needs to be provided as well as correlation to accepted apparatus*

***Results***

* *numerical results (mean value and repeatability) for all tests and controls:*
* *thermal sensitivity*
* *mechanical sensitivity*
* *sensitivity to friction*
* *explosive or non explosive*

### [Study 2] etc.

## Flammable gases (including chemically unstable gases)

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *description of the apparatus and dimensions or reference to the standard or the test method applied;*
* *test temperature*
* *tested concentrations*

***Results***

* *chemical identity of evolved gas*
* *rate of gas evolution (if applicable)*
* *indicate lower and upper explosion limits*
* *flammability results of test at different test concentrations: non-flammable gas, highly flammable gas?*
* *results for a positive control*

### [Study 2] etc.

## Oxidising gases

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *Reference to the standard applied*

***Results***

### [Study 2] etc.

## Gases under pressure

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

***Results***

* *Boiling point*
* *Vapour pressure at 50˚C*
* *Critical temperature*

### [Study 2] etc.

## Flammable liquids

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

***Results***

* *Corrected flashpoint and unit*
* *Data on repeatability and reproducibility as given in the method*
* *Boiling point value (°C) as measured*
* *Pressure value and unit*
* *Rate of temperature increase*
* *Decomposition (if applicable)*
* *Measurement uncertainty (if available)*
* *Explosion limits (if available);*
* *Sustained combustibility (if applicable)*

### [Study 2] etc.

## Flammable solids

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *Indicate if preliminary and/or main test performed*
* *Moisture content*
* *Particle size and distribution*

***Results***

* *Indicate burning time and burning rate*
* *Pass/non pass of the wetted zone (in the case of the UN Test N.1)*

### [Study 2] etc.

## Self-reactive substances

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

***Results***

* *Type of self-reactive substance*
* *Decomposition energy (value and method of determination)*
* *SADT (Self accelerating decomposition temperature) together with the volume the SADT relates to*
* *Detonation properties (Yes/Partial/No)*
* *Deflagration properties (Yes rapidly/Yes slowly/No)*
* *Effect of heating under confinement (Violent/Medium/Low/No)*
* *Explosive power if applicable (Not low/Low/None)*

### [Study 2] etc.

## Pyrophoric liquids

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

***Results***

* *Whether ignition occurs when poured or whether the filter paper is charred*

### [Study 2] etc.

## Pyrophoric solids

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *Particle size and distribution*

***Results***

* *Whether ignition occurs when poured*

### [Study 2] etc.

## Self-heating substances

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *Moisture content*
* *Particle size and distribution (if applicable).*

***Results***

* *Indicate temperature rise*

### [Study 2] etc.

## Substances which in contact with water emit flammable gases

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *Particle size and distribution*

***Results***

* *Indicate whether full test was performed or whether it was terminated at a particular step/stage*
* *Substance identity of evolved gas*
* *Indicate whether the gas evolved ignites spontaneously*
* *Rate of gas evolution (unless the test has been terminated)*

### [Study 2] etc.

## Oxidising liquids

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *test material identity, moisture content*
* *reference substance*
* *preliminary and/or main test used*

***Results***

* *indicate the results of the spontaneous ignition test*
* *indicate the mean pressure rise time for the test substance*
* *indicate the mean pressure rise time for the reference substance(s)*

### [Study 2] etc.

## Oxidising solids

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *Particle size and distribution*
* *Test material identity, moisture content*
* *Sample preparation (e.g. grinding, sieving, drying)*
* *Reference substance*
* *Combustible substance and drying procedure used*
* *Preliminary and/or main test used*

***Results***

### [Study 2] etc.

## Organic peroxides

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

***Results***

* *Type of organic peroxide*
* *SADT (Self accelerating decomposition temperature) together with the volume the SADT related to*
* *Detonation properties (Yes/Partial/No);*
* *Deflagration properties (Yes rapidly/Yes slowly/No);*
* *Effect of heating under confinement (Violent/Medium/Low/No);*
* *Explosive power, if applicable (Not low/Low/None)*

### [Study 2] etc.

## Corrosive to metals

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

* *Test temperature*
* *Tested concentrations*
* *Material type*

***Results***

* *Corrosion rate on steel and/or aluminium surfaces*
* *Exposure time (days)*
* *Mass loss (%)*
* *Intrusion depth (µm)*
* *Test evaluation at the uniform corrosion attack and/or the localised corrosion (e.g. pitting corrosion, shallow pit corrosion)*

### [Study 2] etc.

# TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION)

### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*
* *Physicochemical properties that may be important when assessing toxicokinetics*

***Detailed study summary and results:***

*[Please provide the test material identity, a detailed study and results transparently and objectively as in the original data source without subjective interpretations.]*

***Material and methods***

***Results***

### [Study 2] etc.

# HEALTH HAZARDS

**Acute toxicity**

## Acute toxicity - oral route

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. If an estimation method was used state the equation(s) and/or computer software or other methods applied to calculate the value(s). Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*
* *Physicochemical properties that may be important when assessing acute oral toxicity*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Mode of administration (gavage, in diet, other)*
* *Duration of test/exposure period*
* *Doses/concentration levels, rationale for dose level selection*
* *Post exposure observation period*
* *Control group and treatment*
* *Vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *Statistical methods*

***Results and reliability***

* *Deaths should be those considered to be due to the test substance and should be given in a tabular form showing sex/dose given/no of animals/no of deaths. Information on any other deaths should be provided and justified.*
* *LD50 or LC50 value with confidence limits if calculated*
* *Number of deaths at each dose level*

*Additional information that may be needed to adequately assess data for reliability:*

* *Time of death (provide individual animal time if less than 24 hours after dosing).*
* *Clinical signs: description, severity, reversibility, time of onset and duration at each dose level*
* *Necropsy findings, including doses affected, severity and number of animals affected*
* *Potential target organs (if identified in the report)*
* *Other findings*
* *If both sexes tested, results should be compared*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

## Acute toxicity - dermal route

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. If an estimation method was used state the equation(s) and/or computer software or other methods applied to calculate the value(s). Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*
* *Physicochemical properties that may be important when assessing acute dermal toxicity*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Mode of administration*
* *Duration of test/exposure period*
* *Doses/concentration levels, rationale for dose level selection*
* *Post exposure observation period*
* *Control group and treatment*
* *Vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *Area covered (e.g. x% of body surface)*
* *Occlusion*
* *Total volume applied*
* *Removal of test substance*
* *Statistical methods*

***Results and reliability***

* *Deaths should be those considered to be due to the test substance and should be given in a tabular form showing sex/dose given/no of animals/no of deaths. Information on any other deaths should be provided and justified.*
* *LD50 or LC50 value with confidence limits if calculated*
* *Number of deaths at each dose level*

***Additional information that may be needed to adequately assess data for reliability:***

* *Time of death (provide individual animal time if less than 24 hours after dosing).*
* *Clinical signs: description, severity, reversibility, time of onset and duration at each dose level*
* *Necropsy findings, including doses affected, severity and number of animals affected*
* *Potential target organs (if identified in the report)*
* *Other findings*
* *If both sexes tested, results should be compared*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

## Acute toxicity - inhalation route

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. If an estimation method was used state the equation(s) and/or computer software or other methods applied to calculate the value(s). Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*
* *Particle size of dust and mist given as mean mass aerodynamic diameter (MMAD) and geometric standard deviation or give other specifications*
* *Type or preparation of particles (for studies with aerosols)*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Type of inhalation exposure and test conditions (e.g.: exposure apparatus, method of exposure (“whole body”, “oro-nasal”, or “head only”), exposure data)*
* *Duration of test/exposure period*
* *Doses/concentration levels, (ppmV (parts per million per volume) for gases, mg/l for vapours, mg/l for dusts and mists) and rationale for dose level selection*
* *Analytical verification of test atmosphere concentrations*
* *Post exposure observation period*
* *Control group and treatment*
* *Statistical methods*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

## Skin corrosion/irritation

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*
* *Physicochemical properties that could indicate potential for skin irritation/corrosion (e.g. pH value, physical form, oxidising properties)*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Duration of test/exposure period*
* *Total dose: amount/concentration of test material applied to skin in mg/ml and rationale for dose level selection*
* *Post exposure observation period*
* *Control group and treatment*
* *Vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *Time points at which grading/scoring took place, (e.g. 1, 4 24, 48, 72 hours,14 days, etc)*
* *Grading scale: specify/name of the grading/system used*
* *Preparation of the test site, area covered (e.g. 10% of body surface), shaved or not, abraded or not, pre-treatment of site, patch type: occlusive/semi-occlusive*
* *Removal of test substance (e.g. water or solvent)*
* *Statistical methods*

***Results and discussion***

* *Irritant/corrosive response data: cumulative total and percent responders, preferably in tabular form for each individual animal for each observation time period:*
* *numerical skin grades at 1, 4, 24, 48 and 72 hours*
* *delayed grading scores at 7 to 14 days*
* *Whether the effects observed were reversible*
* *Description of all lesions: erythema/oedema findings, other dermal lesions and/or systemic effects.*
* *Overall irritation score*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## Serious eye damage/eye irritation

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*
* *Physicochemical properties that could indicate potential for eye damage/eye irritation (e.g. pH value, oxidising properties)*
* *Is the substance skin corrosive or skin irritant?*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Duration of test/exposure period*
* *Total dose: amount/concentration of test material applied to skin in mg/ml and rationale for dose level selection*
* *Post exposure observation period*
* *Control group and treatment*
* *Vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *Time points at which grading/scoring took place, (24, 48, 72 hours,21 days, etc)*
* *Tool used to asses scores: hand-slit lamp, biomicroscope, fluorescein, other*
* *Preparation of the test site, area covered (e.g. 10% of body surface), shaved or not, abraded or not, pre-treatment of site, patch type: occlusive/semi-occlusive*
* *Grading scale: specify/name of the grading/system used*
* *Removal of test substance (e.g. water or solvent)*
* *Post exposure observation period*
* *Statistical methods*

***Results and discussion***

* *Irritant/corrosive response data: preferably in tabular form for each individual animal for each observation time period (24, 48 and 72 hours)*
* *Whether the effects observed were fully reversible within an observation period*
* *Description of serious lesions if observed*
* *Narrative description of the degree and nature of irritation/corrosion observed*
* *Description of any non-ocular topical effects observed*
* *Number of animals affected*
* *Overall irritation score*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## Respiratory sensitisation

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Route of induction and challenge induction*
* *Control group and treatment*
* *Induction*
  + *concentration(s) and volume of test substance*
  + *induction vehicle (identification, concentration and volume used)*
  + *note whether more than one dose was given*
  + *the spacing between doses*
  + *mention any pre-treatment that may have been conducted*
* *Challenge*
  + *concentration (if applicable)*
  + *note whether more than one dose was given*
  + *vehicle (if applicable)*

***Results and discussion***

*e.g. measurements of Immunoglobulin E (IgE) and other specific immunological parameters in mice or specific pulmonary responses in guinea pigs.*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, available information on* *the test subjects, route of exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include* ***epidemiological studies, case reports, and data from medical surveillance schemes and national poisons centers.****]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## Skin sensitisation

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Control group and treatment*
* *Route of induction and challenge induction*
  + *injection/topical*
  + *with/without occluded patch*
  + *type of patch used substance*
* *Induction*
  + *concentration(s) and volume of test substance*
  + *induction vehicle (identification, concentration and volume used)*
  + *note whether more than one dose was given*
  + *the spacing between doses*
  + *mention any pre-treatment that may have been conducted*
* *Challenge*
  + *concentration (if applicable)*
  + *note whether more than one dose was given*
  + *vehicle (if applicable)*

***Results and discussion***

* *grading system used (traditional tests); for other tests(i.e., LLNA), identify the endpoint to measure effect (e.g., proliferation of lymph nodes)*
* *statistical methods*
* *conclude whether the test substance is positive, negative or equivocal*
* *data should be summarised in tabular form, showing for each animal the skin reactions at each observation point (e.g. number of animals with skin grades of 0, 1, 2, and 3 at each observation time)*
  + *narrative description of the nature and degree of effects observed*
  + *any histopathological findings*

*Provide additional information that may be needed to adequately assess data for reliability and use, including the following, if available:*

* *whether the substance was a skin irritant at the tested concentrations*
* *incidence of skin scores greater than 1 for test and control groups*
* *sensitisation ratio (maximisation test)*
* *description, severity, time of onset and duration of clinical signs and/or lesions at the site of contact at each dose level*
* *results of rechallenge*

*For the LLNA study, provide the following additional information:*

* *group mean disintegrations/minute and standard deviation*
* *stimulation index or fold increase for each group (including positive control) relative to negative control*
* *pooled or grouped approach*
* *statistical comparisons of groups mean dpms compared to controls*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Provide identity of the test substance, test subjects, route of administration, size of the population exposed, extent of exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical history data and case reports, medical surveillance and reporting schemes.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## Germ cell mutagenicity

### In vitro data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design.*

* *number of replicates*
* *number of doses, justification of dose selection*
* *positive and negative control groups and treatment*
* *details on slide preparation*
* *number of metaphases analysed*
* *justification for choice of vehicle*
* *solubility and stability of the test substance in vehicle if known*
* *description of follow up repeat study*
* *criteria for evaluating results (e.g. cell evaluated per dose group, criteria for scoring aberrations)*

*Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*

***Administration/exposure***

* *Strain or cell type or cell line, target gene if applicable*
* *Type and composition of metabolic activation system:*
  + *species and cell type*
  + *quantity*
  + *induced or not induced*
  + *chemicals used for induction*
  + *co-factors used*
* *Test concentrations, and reasoning for selection of doses if applicable*
* *Vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *Statistical methods*

***Results and discussion***

* *Justification should be given for choice of tested dose levels (e.g. dose-finding studies)*
* *Cytotoxic concentrations with and without metabolic activation*
* *Genotoxic effects (e.g. positive, negative, unconfirmed, dose-response, equivocal) with and without metabolic activation*
* *Concurrent negative (solvent/vehicle) and positive control data*
* *Indicate test-specific confounding factors such as pH, osmolarity, whether substance is volatile, water soluble, precipitated, etc., particularly if they affect the selection of test concentrations or interpretation of the results*
* *Statistical results*
* *Provide information that may be needed to adequately assess data for reliability*
  + *frequency of reversions/mutations/aberrations, polyploidy*
  + *mean number of revertant colonies per plate and standard deviation, number of cells with chromosome aberrations and type of chromosome aberrations given separately for each treated and control culture,*
  + *precipitation concentration if applicable*
  + *mitotic index*

#### [Study 2] etc.

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Doses/concentration levels, vehicle, rational for dose selection*
* *Vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *Details on test system and conditions, and details on route of administration, exposure*
* *Actual doses (mg/kg bw/day) and conversion factor from diet/drinking water test substance concentration (ppm) to the actual dose, if applicable*
* *Duration of study, frequency of treatment, sampling times and number of samples*
* *Control groups and treatment*
* *Positive and negative (vehicle/solvent) control data*
* *Methods of slide preparation*
* *Criteria for scoring and number of cells analysed per animal*
* *Statistical methods*

***Results and discussion***

* *Effect on mitotic index or PCE/NCE (polychromatic erythrocyte/normochromatic erythrocyte) ratio by dose level by sex (if applicable)*
* *Genotoxic effects (positive, negative, unconfirmed, dose-response, equivocal)*
* *Concurrent positive control data*
* *Statistical results*
* *Describe additional information that may be needed to adequately assess data for reliability and use, including the following, if available: Mortality at each dose level by sex:*
  + *mutant/aberration/mPCE/polyploidy frequency*
  + *description, severity, time of onset and duration of clinical signs at each dose level and sex*
  + *body weight changes by dose and sex*
  + *food/water consumption changes by dose and sex*
* *Discuss if it can be verified that the test substance reached the general circulation or target tissue, if applicable.*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Provide identity of the test substance, test subjects, route of administration, size of the population exposed, extent of exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies and case reports. Generally, cells circulating in blood are studied to detect genetic alterations.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## Carcinogenicity

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Route of administration – oral (gavage, drinking water, feed), dermal, inhalation (aerosol, vapour, gas, particulate), other*
* *duration of test/exposure period*
* *doses/concentration levels, rationale for dose level selection*
* *frequency of treatment*
* *control group and treatment*
* *historical control data*
* *post exposure observation period*
* *vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *test substance formulation/diet preparation, achieved concentration, stability and homogeneity of the preparation*
* *actual doses (mg/kg bw/day) and conversion factor from diet/drinking water test*
* *substance concentration (ppm) to the actual dose, if applicable*
* *satellite groups and reasons they were added*

*For inhalation studies:*

* *type of inhalation exposure and test conditions (e.g.: exposure apparatus)*
* *method of exposure (“whole body”, “oro-nasal”, or “head only”), exposure data*
* *analytical verification of test atmosphere concentrations*
* *particle size (for studies with aerosols, indicate mass median aerodynamic diameter and geometric standard deviation or give other specifications)*
* *type or preparation of particles (for studies with aerosols)*

*For dermal studies:*

* *area covered (e.g. 10% of body surface)*
* *occlusion (e.g. semi-occlusive)*
* *total volume applied*
* *removal of test substance (e.g. water or solvent)*

***Results and discussion***

*Describe the relevant findings. If no effects occurred, explicitly note "No effects".*

* *mortality and time to death (indicate number died per sex per dose and time to death)*
* *clinical signs*
* *body weight gain*
* *food/water consumption*
* *ophthalmoscopic examination*
* *clinical chemistry*
* *haematology*
* *urinalysis*
* *organ weights*
* *necropsy findings: nature and severity*
* *histopathological findings: nature and severity*
* *tumour incidence data by sex, dose and tumour type*
* *local or multi-site responses*
* *progression of lesions to malignancy*
* *gender and/or species-specific responses*
* *tumour incidence data by sex, dose and tumour type*
* *mode of action (genotoxic, non-genotoxic)*
* *toxic response data by sex and dose*
* *tumour latency*
* *statistical methods and results (unless already described with specific test results above)*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

### *In vitro* data (e.g. in vitro germ cell and somatic cell mutagenicity studies, cell transformation assays, gap junction intercellular communication tests)

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

### Other data (e.g. studies on mechanism of action)

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## Reproductive toxicity

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *Route of administration – oral (gavage, drinking water, feed), dermal, inhalation (aerosol, vapour, gas, particulate), other*
* *duration and frequency of test/exposure period*
* *doses/concentration levels, rationale for dose level selection*
* *control group and treatment*
* *historical control data if available*
* *vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *test substance formulation/diet preparation, achieved concentration, stability and homogeneity of the preparation*
* *actual doses (mg/kg bw/day) and conversion factor from diet/drinking water test*
* *substance concentration (ppm) to the actual dose, if applicable*

*For inhalation studies:*

* *type of inhalation exposure and test conditions (e.g.: exposure apparatus)*
* *method of exposure (“whole body”, “oro-nasal”, or “head only”), exposure data*
* *analytical verification of test atmosphere concentrations*
* *particle size (for studies with aerosols, indicate mass median aerodynamic diameter and geometric standard deviation or give other specifications)*
* *type or preparation of particles (for studies with aerosols)*

*For dermal studies:*

* *area covered (e.g. 10% of body surface)*
* *occlusion (e.g. semi-occlusive)*
* *total volume applied*
* *removal of test substance (e.g. water or solvent)*

***Description of test design:***

* *details on mating procedure (M/F ratios per cage, length of cohabitation, proof of pregnancy)*
* *premating exposure period for males and females (P and F1)*
* *dosing schedules and pre and post dosing observation periods for P, F1 and F2, as appropriate*
* *standardization of litters (yes/no and if yes, how and when)*
* *parameters assessed for P and F1*
* *estrous cycle length and pattern, sperm examination, clinical observations performed and frequency*
* *parameters assessed for F1 and F2*
* *clinical observations performed and frequency, organs examined at necropsy, others (e.g. anogenital distance)*
* *post exposure observation period*

***Results and discussion***

*Describe the relevant findings. If no effects occurred, explicitly note "No effects".*

* *actual dose received by dose level by sex if known*
* *statistical treatment of results, where appropriate*
* *provide data on any dose-related observations*

*For P and F1 adults (per dose):*

* *number of animals at the start of the test and matings*
* *time of death during the study and whether animals survived to termination*
* *body weight data for P and F1 animals selected for mating*
* *body weight at sacrifice and absolute and relative organ weight data for the parental animals*
* *toxic response data by sex and dose including indices of mating, fertility, gestation, birth, viability and lactation; indicate the numbers used in calculating the indices*
* *toxic or other effects on reproduction, offspring, postnatal growth*
* *clinical observations: description, severity, time of onset and duration*
* *haematological and clinical biochemistry findings if available*
* *effects on sperm*
* *number of P and F1 females cycling normally and cycle length*
* *duration of gestation (calculated from day 0 of pregnancy)*
* *precoital interval (number of days until mating and number of estrous periods until mating)*
* *number of implantations, corpora lutea, litter size*
* *number of pre- and post-implantation loss*
* *number of dams with abortions, early deliveries, stillbirths, resorptions and/or dead fetuses*
* *number of live births*
* *data on functional observations*
* *necropsy findings*
* *histopathological findings: nature and severity*
* *body weight change and gravid uterine weight, including optionally, body weight change corrected for gravid uterine weight*
* *other organ weight changes if available*

*For F1 and F2 pups/litters (per dose):*

* *mean number of live pups (litter size)*
* *sex ratio*
* *viability index (pups surviving 4 days/total births)*
* *survival index at weaning*
* *mean litter or pup weight by sex and with sexes combined*
* *external, soft tissue and skeletal malformations and other relevant alterations*
* *number and percent of fetuses and litters with malformations (including runts) and/or variations as well as description and incidences of malformations and main variations (and/or retardations)*
* *data on physical landmarks in pups and other postnatal developmental data*
* *data on functional observations*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

### Other data (e.g. studies on mechanism of action)

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## Specific target organ toxicity – single exposure

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *route of administration – oral (gavage, drinking water, feed), dermal, inhalation (aerosol, vapour, gas, particulate), other*
* *duration and frequency of test/exposure period*
* *doses/concentration levels, rationale for dose level selection*
* *post exposure observation period*
* *vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *control group and treatment*
* *test substance formulation/diet preparation, achieved concentration by sex and dose level, stability and homogeneity of the preparation*
* *actual dose (mg/kg bw) and conversion factor from diet/drinking water test substance concentration (ppm) to the actual dose, if applicable*
* *statistical methods*

*For inhalation studies:*

* *type of inhalation exposure and test conditions (e.g.: exposure apparatus)*
* *method of exposure (“whole body”, “oro-nasal”, or “head only”), exposure data*
* *analytical verification of test atmosphere concentrations*
* *particle size (for studies with aerosols, indicate mass median aerodynamic diameter and geometric standard deviation or give other specifications)*
* *type or preparation of particles (for studies with aerosols)*

*For dermal studies:*

* *area covered (e.g. 10% of body surface)*
* *occlusion (e.g. semi-occlusive)*
* *total volume applied*
* *removal of test substance (e.g. water or solvent)*

***Results and discussion***

*Describe the relevant findings and toxic response/effects by sex and dose level. If no effects occurred, explicitly note "No effects".*

* *body weight and body weight changes*
* *food/water consumption*
* *description, severity, time of onset and duration of clinical signs (reversible, irreversible, immediate, delayed)*
* *sensory activity, grip strength and motor activity assessments (when available)*
* *ophthalmologic findings: incidence and severity*
* *haematological findings: incidence and severity*
* *clinical biochemistry findings: incidence and severity*
* *gross pathology findings: incidence and severity*
* *histopathology findings: incidence and severity*
* *mortality and time to death (if occurring)*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, available information on* *the test subjects, route of exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, data from national poisons centers and volunteer studies.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## Specific target organ toxicity – repeated exposure

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.*

*In addition to standard 28-day, 90-day and 2-year animal studies, other long-term exposure studies such as carcinogenicity, neurotoxicity and reproductive toxicity studies may provide evidence on specific target organ toxicity following repeated exposure.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

* *route of administration – oral (gavage, drinking water, feed), dermal, inhalation (aerosol, vapour, gas, particulate), other*
* *duration and frequency of test/exposure period*
* *doses/concentration levels, rationale for dose level selection*
* *post exposure observation period*
* *vehicle: identification, concentration and volume used, justification of choice of vehicle (if other than water)*
* *control group and treatment*
* *test substance formulation/diet preparation, achieved concentration by sex and dose level, stability and homogeneity of the preparation*
* *actual dose (mg/kg bw/day) and conversion factor from diet/drinking water test substance concentration (ppm) to the actual dose, if applicable*
* *statistical methods*

*For inhalation studies:*

* *type of inhalation exposure and test conditions (e.g.: exposure apparatus)*
* *method of exposure (“whole body”, “oro-nasal”, or “head only”), exposure data*
* *analytical verification of test atmosphere concentrations*
* *particle size (for studies with aerosols, indicate mass median aerodynamic diameter and geometric standard deviation or give other specifications)*
* *type or preparation of particles (for studies with aerosols)*

*For dermal studies:*

* *area covered (e.g. 10% of body surface)*
* *occlusion (e.g. semi-occlusive)*
* *total volume applied*
* *removal of test substance (e.g. water or solvent)*

***Results and discussion***

*Describe the relevant findings and toxic response/effects by sex and dose level. If no effects occurred, explicitly note "No effects".*

* *body weight and body weight changes*
* *food/water consumption*
* *description, severity, time of onset and duration of clinical signs (reversible, irreversible, immediate, delayed)*
* *sensory activity, grip strength and motor activity assessments (when available)*
* *ophthalmologic findings: incidence and severity*
* *haematological findings: incidence and severity*
* *clinical biochemistry findings: incidence and severity*
* *gross pathology findings: incidence and severity*
* *histopathology findings: incidence and severity*
* *mortality and time to death (if occurring)*

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, available information on* *the test subjects, route of exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, case reports, and data from medical surveillance schemes and national poisons centers.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## Aspiration hazard

### Animal data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test substance***

* *Indicate if the test material used in the study is equivalent to the substance identified in the CLH dossier*
* *EC number (if different from the substance identified in the CLH dossier)*
* *CAS number (if different from the substance identified in the CLH dossier)*
* *Degree of purity*
* *Impurities (or a note that the impurities do not affect the classification)*
* *Batch number*

***Test animals***

* *Species/strain/sex*
* *No. of animals per sex per dose*
* *Age and weight at the study initiation*

***Administration/exposure***

***Results and discussion***

#### [Study 2] etc.

### Human data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations. Human studies may include epidemiological studies, clinical data and case reports, routine data collection, biological monitoring/personal sampling and published or unpublished industry studies.]*

#### [Study 2] etc.

### Other data

#### [Study 1]

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design. Please state if the study is GLP compliant or not.]*

***Test type***

*[Please provide a detailed study summary including the test type, identity of the test substance, test subjects, route of administration, exposure and results transparently and objectively as in the original data source without subjective interpretations.]*

#### [Study 2] etc.

## ENDOCRINE DISRUPTION FOR HUMAN HEALTH

### Animal data

*Please see under sections 3.9, 3.10 or 3.12 of this document and ECHA/EFSA Guidance on Endocrine disruptors for additional ED related parameters to be reported (ECHA/EFSA, 2018).*

**[Study 1]**

**[Study 2] etc.**

### Human data

*Please see under sections 3.9, 3.10 or 3.12 of this document and ECHA/EFSA Guidance on Endocrine disruptors for additional ED related parameters to be reported (ECHA/EFSA, 2018).*

**[Study 1]**

**[Study 2] etc.**

### Other data (e.g. in vitro data, in silico data, mechanistic data)

*Please see under sections 3.9, 3.10 or 3.12 of this document and ECHA/EFSA Guidance on Endocrine disruptors for additional ED related parameters to be reported (ECHA/EFSA, 2018).*

**[Study 1]**

**[Study 2] etc.**

# ENVIRONMENTAL HAZARDS

## Degradation



### Ready biodegradability (screening studies)

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Details on inoculum (nature and sampling site(s), concentration and any pre-conditioning treatment – any adaptation to be mentioned specifically)*
* *• Duration of test*
* *• Details on test conditions (composition of medium, test temperature, pH, CEC (meq/100g), continuous darkness: yes/no, etc.)*
* *• Oxygen conditions (if relevant, the oxygen uptake of the inoculum blank (mg 02/l) after 28 days or oxygen depletion in the inoculum blank after 28 days and the residual concentration of oxygen in the test bottles)*
* *• Initial test substance concentration, vehicle used, pre-acclimatisation*
* *• Information on controls and blank system used*
* *• Details on sampling (frequency, method and sterility)*
* *• Details on analytical method to measure biodegradation*
* *• Identity of reference substance(s) used*
* *• Parameter followed for degradation estimation*
* *• Method of calculating measured concentrations (arithmetic mean, geometric mean, etc.)*

***Results:***

* *• Degradation % after time, including the result at the end of a 10-day window (does not apply to the MITI method; see the test method for the definition of the 10-day window)*
* *• Degradation results presented preferably with graphs of percentage degradation against time for the test and reference substances, the lag phase, degradation phase, the 10-day window and slope; if no graph then at least indication of the duration of the lag phase, the degradation phase and location of the 10-day window within the test period*
* *• Replicate values of the degradation % of the test chemical at the degradation rate at the plateau, in the end of test, and/or after 10-day window, as appropriate*
* *• Degradation % of the reference compound by day 14 (if relevant also after 7 days)*
* *• Degradation % within 14 days in a toxicity test containing both the test substance and a reference compound*
* *• Specific chemical analytical data, if available*
* *• Any inhibition phenomena or unusual observations or other information affecting the results*
* *• Breakdown products: yes/no, if yes description of breakdown products and the information whether they are transient or stable*
* *• If relevant, inorganic carbon (IC) content of the test substance suspension in the mineral medium at the beginning of the test and total carbon (TC) content;*
* *• If relevant, total C02 evolution in the inoculum blank at the end of the test.*

**[Study 2] etc.**

### BOD5/COD

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

**[Study 2] etc.**

### Aquatic simulation tests

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Details on water/soil/sediment sample (e.g. location and description of sampling site including, if possible, contamination history; if relevant: organic C, clay content and soil texture, Cation Exchange Capacity and pH)*
* *• Duration of test*
* *• Details on test conditions (e.g. test temperature, pH, continuous darkness: yes/no, etc.)*
* *• Oxygen conditions*
* *• Amount of test substance applied, test concentration and reference substance concentration, solubilising agent if relevant*
* *• Information on controls and blank system used*
* *•Details on sampling: (e.g. frequency, method and sterility)*
* *• Repeatability and sensitivity of the analytical methods used including the limit of detection*
* *• (LOD) and the limit of quantification (LOQ), recovery %*
* *• Identity of reference substance(s) used*

***Results:***

* *• Half-life or DT50, DT75 and DT90 for the test substance and, where appropriate, for major transformation products including confidence limits,*
* *• Averages of the results observed in individual replicates, for example length of lag phase, degradation rate constant and degradation half-life*
* *• The results of the final mass balance check*
* *• Where appropriate, identification, molar concentration and percentage of applied of major transformation products, a proposed pathway of transformation*
* *• Where applicable, an assessment of transformation kinetics for the test substance and characterisation of non-extractable (bound) radioactivity or residues in soil*
* *• Where applicable, degradation % and time interval of degradation of the reference compound*

**[Study 2] etc.**

### Other degradability studies

*(e.g. field investigations and monitoring data, inherent and enhanced Ready biodegradability tests, water, water-sediment and soil degradation data, hydrolysis, photochemical degradation, rapid environmental transformation of metals or metal compounds)*

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

**[Study 2] etc.**

## Bioaccumulation

### Bioaccumulation test on fish

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species, origin and whole body lipid content*
* *• Test conditions: pre-treatment, acclimatisation of test species; durations of uptake and depuration phases; temperature; photoperiod and light intensity; dissolved oxygen concentration; pH (through all the test), hardness, total solids, total organic carbon and salinity of the water; vehicles, solvents or dispersants used (if any); feeding details*
* *• Test design: number and size of test chambers, water volume replacement rate; number of animals per concentration; number of males and females used (together with weight and age); loading rate*
* *• Water quality measurements regime and results*
* *• Substance toxicity to the fish species to be used in the test*
* *• Details on the analytical methods used for determination of the substance in water and test animals*

***Results***

* *• Uptake and depuration curves (optional)*
* *• Time to steady state*
* *• Cf (concentration in fish) and Cw (concentration in water) - with standard deviation and range, if appropriate, for all sampling times (Cf expressed in mg/g wet weight of whole body or specified tissues thereof e.g. lipid, and Cw in mg/ml). Cw values for the control series (background should also be reported)*
* *• Steady state BCF value and unit; if available kinetic BCF. BCF should be expressed on tissue type (e.g. whole body, muscle, fillet, liver) and on lipid content, confidence limits and standard deviation (as available) and methods of computation/data analysis for each concentration of test substance used should be reported*
* *• Time of plateau / % of steady-state*
* *• Mortalities and behavioural observations (in test and control)*
* *• Nominal or measured concentrations (monitoring of test concentrations over time in water and test organisms)*
* *• Correction factors and normalisation of results to lipid content*
* *• Correction for growth dilution*

**[Study 2] etc.**

### Bioaccumulation test with other organisms

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary and results transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species, origin and whole body lipid content*
* *• Test conditions: pre-treatment, acclimatisation of test species; durations of uptake and depuration phases; temperature; photoperiod and light intensity; dissolved oxygen concentration; pH (through all the test), hardness, total solids, total organic carbon and salinity of the water; vehicles, solvents or dispersants used (if any); feeding details*
* *• Test design: number and size of test chambers, water volume replacement rate; number of animals per concentration; number of males and females used (together with weight and age); loading rate*
* *• Water quality measurements regime and results*
* *• Substance toxicity to the fish species to be used in the test*
* *• Details on the analytical methods used for determination of the substance in water and test animals*

***Results***

* *• Uptake and depuration curves (optional)*
* *• Time to steady state*
* *• Cf (concentration in fish) and Cw (concentration in water) - with standard deviation and range, if appropriate, for all sampling times (Cf expressed in mg/g wet weight of whole body or specified tissues thereof e.g. lipid, and Cw in mg/ml). Cw values for the control series (background should also be reported)*
* *• Steady state BCF value and unit; if available kinetic BCF. BCF should be expressed on tissue type (e.g. whole body, muscle, fillet, liver) and on lipid content, confidence limits and standard deviation (as available) and methods of computation/data analysis for each concentration of test substance used should be reported*
* *• Time of plateau / % of steady-state*
* *• Mortalities and behavioural observations (in test and control)*
* *• Nominal or measured concentrations (monitoring of test concentrations over time in water and test organisms)*
* *• Correction factors and normalisation of results to lipid content*
* *• Correction for growth dilution*

**[Study 2] etc.**

## Acute toxicity

### Short-term toxicity to fish

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species and origin*
* *• Acclimation period*
* *• Size and age of fish*
* *• Test conditions (e.g. dissolved oxygen, pH, hardness, type of water, temperature, lighting, test system, solubilising agent, static/ semi-static/ flow-through etc.)*
* *• If semi-static: renewal time, if flow-through: flow rate or renewal time*
* *• Tested doses*
* *• Test duration/total exposure duration*
* *• Test design (e.g. test concentrations throughout the test, number/type of controls, number of replicates, number of animals per replicate and loading, etc.)*
* *• Preliminary test, if conducted*

***Results***

* *• Observations in the controls (mortality, number of dead fish, abnormal appearance and behaviour etc.)*
* *• Observations in the test system (mortality, number of dead fish, abnormal appearance and behaviour etc.)*
* *• Monitoring of test concentrations*
* *• Other measurements throughout the test (e.g. dissolved oxygen, pH, temperature, etc.)*
* *• LC50 at 24, 48, 72 and 96 hours, dose-response relationships, description of statistical analysis performed*

**[Study 2] etc.**

### Short-term toxicity to aquatic invertebrates

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species and origin*
* *• Species life stage*
* *• Test conditions (e.g. dissolved oxygen, pH, hardness, type of water, temperature, lighting, test system, solubilising agent, etc.)*
* *• Test duration/total exposure duration*
* *• Acclimation period*
* *• Test design (e.g. test concentrations, number/type of controls, number of replicates, number of animals per vessel, feeding pattern, reference substance used for the organisms sensitivity check, etc.)*

***Results***

* *• Observations in the controls (e.g. immobilised organisms etc.)*
* *• Observations in the test system (e.g. immobilised organisms etc.)*
* *• Monitoring of test concentrations*
* *• Other measurements throughout the test (e.g. dissolved oxygen, pH, temperature etc.)*
* *• EC50, IC50 or LC50, dose-response relationships, description of statistical analysis performed*

**[Study 2] etc.**

### Algal growth inhibition tests

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species*
* *• Initial cell concentration*
* *• Test conditions (e.g. temperature, lighting, test medium, pH, test system, solubilising agent, etc.)*
* *• Test duration/total exposure duration*
* *• Test design (e.g. test concentrations, number/type of controls, number of replicates, etc)*
* *• Controls conditions (pH, etc.)*

***Results***

* *• Observations in the controls (e.g. increase in biomass, growth rate, etc.)*
* *• Details on the determination of algal biomass (e.g. method for cell counting, cell density, chlorophyll, etc.)*
* *• Determination of growth rates*
* *• Growth curves (e.g. evidence of exponential growth in the controls, growth rate evolution throughout the test in the test vessels, etc.)*
* *• Other effects (e.g. microscopic appearance of algal cells, changes in size, shape or colour, percent mortality of cells, etc.)*
* *• Monitoring of test concentrations*
* *• Other measurements throughout the test (temperature, pH, etc.)*
* *• EC50, EC10 or NOEC, dose-response relationships, description of statistical analysis performed*

**[Study 2] etc.**

### *Lemna* sp. growth inhibition test

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species*
* *• Initial frond number*
* *• Test conditions (e.g. temperature, lighting, test medium, pH, test system, solubilising agent, etc.)*
* *• Test duration/total exposure duration*
* *• Test design (e.g. test concentrations, number/type of controls, number of replicates, etc.)*

***Results***

* *• Observations in the controls*
* *• Observations (e.g. frond number, frond area, dry or fresh weight, chlorophyll-a, etc.)*
* *• Determination of growth rates*
* *• Other effects (e.g. frond and root size and appearance, necrosis, chlorosis, gibbosity, loss of buoyancy, etc.)*
* *• Monitoring of test concentrations*
* *• Other measurements throughout the test (e.g. pH, light intensity, temperature, etc.)*

*• EC50, EC10 or NOEC, dose-response relationships, description of statistical analysis performed*

**[Study 2] etc.**

## Chronic toxicity

### Fish early-life stage (FELS) toxicity test

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species and origin*
* *• Acclimation period*
* *• Size and age of fish*
* *• Test conditions (e.g. dissolved oxygen, pH, hardness, type of water, temperature, lighting, feeding, test system, solubilising agent and its effects, etc.)*
* *• Preliminary test*
* *• Test duration/total exposure duration*
* *• Test design (e.g. test concentrations, number of controls, number of replicates, number of eggs, per replicate and loading, etc.)*

***Results***

* *• Observations in the controls (survival of the fertilised eggs, etc.)*
* *• Observations (hatching success and post-hatch survival, abnormal appearance and behaviour, individual weights at the end of the test, etc.)*
* *• Monitoring of test concentrations*
* *• Other measurements throughout the test (e.g. dissolved oxygen, pH, hardness, temperature, etc.)*
* *• Expression of results: cumulative mortality; number of healthy fish at the end of the test; time to start of hatching and end of hatching; numbers of larvae hatching each day; number and description of morphological abnormalities; number and description of behavioural effects; length and weight of surviving animals*
* *• EC10 or NOEC, dose-response relationships, description of statistical analysis performed*

**[Study 2] etc.**

### Fish short-term toxicity test on embryo and sac-fry stages

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species and origin*
* *• Acclimation period*
* *• Test conditions (e.g. dissolved oxygen, pH, hardness, type of water, temperature, lighting, test system, solubilising agent, etc.)*
* *• Preliminary test*
* *• Test duration/total exposure duration*
* *• Test design (e.g. test concentrations, number of controls, number of replicates, loading, etc.)*

***Results***

* *• Observations in the controls (survival of the fertilised eggs, etc.)*
* *• Observations (e.g. hatching success and post-hatch survival, abnormal appearance and behaviour, individual weights at the end of the test, etc.)*
* *• Monitoring of test concentrations*
* *• Other measurements throughout the test (e.g. dissolved oxygen, pH, hardness, temperature, etc.)*
* *• Expression of results: cumulative mortality; number of healthy larvae at the end of the test; time to start of hatching and end of hatching; numbers of larvae hatching each day; number and description of morphological abnormalities; number and description of behavioural effects; length and weight of surviving animals*
* *• EC10 or NOEC, dose-response relationships, description of statistical analysis performed*

**[Study 2] etc.**

### Aquatic Toxicity – Fish, juvenile growth test

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier.*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species and origin*
* *• Acclimation period*
* *• Weight of fish at the beginning of the test*
* *• Test conditions (e.g. dissolved oxygen, pH, hardness, type of water, temperature, lighting, feeding, test system8, solubilising agent, etc.)*
* *• Preliminary test*
* *• Test duration/total exposure duration*
* *• Test design (e.g. test concentrations, number of controls, number of replicates, loading, etc.)*

***Results***

* *• Observations in the controls: (e.g. mortality, growth rate of control organisms, etc.)*
* *• Observations: growth (weight), any abnormalities (e.g. mortality, appearance, behaviour)*
* *• Monitoring of test concentrations*
* *• Other measurements throughout the test (e.g. dissolved oxygen, pH, hardness, temperature, etc.)*
* *• Expression of results: growth rate, observations on mortality or abnormalities*
* *• EC10 or NOEC, dose-response relationships, description of statistical analysis performed*

**[Study 2] etc.**

### Chronic toxicity to aquatic invertebrates

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

***Test type***

*[Test guideline followed and any significant deviations from the guideline if applicable. If no guideline was followed, include a description of the test design (see below). Please state if the study is GLP compliant or not.]*

***Test substance***

* *• Indicate if the test material used in the study is equivalent to the substance identified in the C&L dossier*
* *• EC number (if different from the substance identified in the C&L dossier)*
* *• CAS number (if different from the substance identified in the C&L dossier)*
* *• Degree of purity*
* *• Impurities (or a note that the impurities do not affect the classification)*
* *• Batch number*

*[where relevant, reference to table 5 of the C&L report may be sufficient]*

***Materials and methods***

* *• Test species and origin*
* *• Acclimation period*
* *• Species life stage*
* *• Test conditions (e.g. dissolved oxygen, pH, hardness, TOC, type of water, temperature, lighting, feeding, test system10, solubilising agent, etc.)*
* *• Preliminary test*
* *• Test duration*
* *• Test design (e.g. test concentrations, number of controls, number of replicates, number of animals, etc.)*

***Results***

* *• Observations in the controls: (e.g. number of juveniles per parent, presence of living males, ephippia produced, etc.)*
* *• Observations in the test system: number of offspring (daily count), number of dead parents (daily count), any other observed effects (e.g. growth of parents)*
* *• Monitoring of test concentrations*
* *• Other measurements throughout the test (dissolved oxygen, pH, hardness, temperature)*
* *• Expression of results: e.g. total number of living offspring produced per parent animal alive at the end of the test (including control)*
* *• EC10 or NOEC, dose-response relationships, description of statistical analysis performed*

**[Study 2] etc.**

### Chronic toxicity to algae or aquatic plants

*[See short-term toxicity]*

## Acute and/or chronic toxicity to other aquatic organisms

### OECD TG 218: Sediment-Water Chironomid Toxicity Using Spiked Sediment and

### OECD TG 219: Sediment-Water Chironomid Toxicity Using Spiked Water

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

* *• Number of emerged male and female midges per vessel and per day*
* *• Number of larvae which failed to emerge as midges per vessel*
* *• Mean individual dry weight of larvae per vessel, and per instar, if appropriate*
* *• Development rate of fully emerged midges per replicate and treatment rate*
* *• % emergence rate per replicate and test concentration*

**[Study 2] etc.**

### OECD TG 225: Sediment-Water Lumbriculus Toxicity Test Using Spiked Sediment

**[Study 1]**

***Study reference:***

*[Authors, title of the article, journal, year, as appropriate]*

***Detailed study summary and results:***

*[Please provide a detailed study summary transparently and objectively as in the original data source without subjective interpretations.]*

* *• Number of worms per replicate at the beginning and end of the test*
* *• Abnormal behaviour if any*
* *• Dry weight of the worms per test chamber*
* *• Total number, and if determined, number of complete and incomplete worms*

*• Measured test concentrations*

*• Estimates of the toxic endpoint(s) (e.g. ECx and confidence intervals, NOEC. LOEC) dose- response relationships, description of statistical analysis performed*

**[Study 2] etc.**

## ENDOCRINE DISRUPTION FOR THE ENVIRONMENT

### Animal data

Please see under sections 4.1 to 4.5 of this document and ECHA/EFSA Guidance on Endocrine disruptors for additional ED related parameters to be reported (ECHA/EFSA, 2018).

**[Study 1]**

**[Study 2] etc.**

### Other data (e.g. in vitro data, in silico data, mechanistic data)

**[Study 1]**

**[Study 2] etc.**

# PERSISTENT, BIOACCUMULATIVE AND TOXIC (PBT) OR VERY PERSISTENT, VERY BIOACCUMULATIVE (VPVB) PROPERTIES UNDER CLP ANNEX I, 4.3

## [Add your text here]

*Please add any relevant subheading and description of a study considered necessary for PBT or vPvB assessment that needs to be explained in more detail than in the actual CLH report.*

*Please see under sections 4.1 or 4.2 of this document how parameters can be reported.*

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

## [Add your text here]

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

## [Add your text here]

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

# PERSISTENT, MOBILE AND TOXIC (PMT) OR VERY PERSISTENT, VERY MOBILE (vPvM) PROPERTIES UNDER CLP ANNEX I, 4.4

## [Add your text here]

*Please add any relevant subheading and description of a study considered necessary for PMT or vPvM assessment that needs to be explained in more detail than in the actual CLH report.*

*Please see under section 4.1 of this document how parameters can be reported.*

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

## [Add your text here]

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

## [Add your text here]

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

### [Add your text here]

**[Study 1]**

**[Study 2] etc.**

# ADDITIONAL HAZARDS: HAZARDOUS TO THE OZONE LAYER

*Please add any relevant description of a study considered necessary for hazardous to the ozone layer assessment that needs to be explained in more detail than in the actual CLH report.*